MedTrace Logo

SADBE for Congenital Melanocytic Nevi

NCT04999631 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-05-22

No results posted yet for this study

Summary

A study to evaluate the safety and efficacy topical squaric acid dibutylester (SADBE) for the neoadjuvant treatment of congenital melanocytic nevi (CMN).

Conditions

  • Congenital Melanocytic Nevus

Interventions

DRUG

Squaric Acid Dibutyl Ester

Topical squaric acid dibutyl ester (SADBE) dissolved in ethanol at 0.2% concentration.

DRUG

Ethanol Solution

Control

Sponsors & Collaborators

Principal Investigators

  • Elena B. Hawryluk · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-01-01
Primary Completion
2030-01-01
Completion
2030-06-01
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04999631 on ClinicalTrials.gov